NCT03631407: A reported trial by Merck Sharp & Dohme LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03631407 |
|---|---|
| Title | A Phase 2 Trial to Evaluate the Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 24, 2018 |
| Completion date | June 8, 2021 |
| Required reporting date | June 8, 2022, midnight |
| Actual reporting date | May 11, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |